• Explore /
  • Poster
  • / Longitudinal mutational analysis of <em>TP53</em> in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.

Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.

Abstract Poster

Authors

Alexander Peltzer

Alexander Peltzer

Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Translational Medicine & Clinical Pharmacology, Biberach an Der Riss, Germany

Alexander Peltzer , Raphael Hesse , Mrinal M. Gounder , Noboru Yamamoto , Manish R. Patel , Scott Laurie , Todd Michael Bauer , Michael Teufel , Junxian Geng , Patricia LoRusso

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Clinical Trial Registration Number

NCT03449381

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3036)

DOI

10.1200/JCO.2023.41.16_suppl.3036

Abstract #

3036

Poster Bd #

234

Abstract Disclosures

Similar Posters

First Author: Maria Pia Morelli

First Author: Patricia LoRusso

First Author: Curtis Robert Chong

First Author: Todd Michael Bauer